Author

E. J. Tolosa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Organism:mouse· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

M. E. Fernandez-Zapico· 2 shared A. A. Mangaonkar· 1 shared A. Buradkar· 1 shared A. Califano· 1 shared A. Curiel-Garcia· 1 shared A. Ma· 1 shared A. Muir· 1 shared A. R. Decker-Farrell· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. E. Fernandez-Zapico

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression

M. C. Hasselluhn, A. R. Decker-Farrell, L. Vlahos, D. H. Thomas, A. Curiel-Garcia, H. C. Maurer, U. N. Wasko, L. Tomassoni, S. A. Sastra, C. F. Palermo, T. C. Dalton, A. Ma, F. Li, E. J. Tolosa, H. Hibshoosh, , K. P. Olive

The paper identifies a paracrine signaling cascade involving SHH, WNT, and VEGF that suppresses angiogenesis in pancreatic cancer using tumor explant models.

bioRxiv · Mar 2, 2023Cancer Biology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology